Synopsis 27
Background: Fidaxomicin treatment reduces risk of recurrent Clostridium difficile infection (CDI) 28 compared with vancomycin. Extending duration of fidaxomicin therapy may further reduce 29 recurrence. We compared the efficacy of four extended fidaxomicin regimens in an in-vitro model of 30
CDI. 31
Methods: Four gut models were primed with human faeces, spiked with C. difficile spores (PCR 32 moderate and severe CDI, respectively. 8 However, treatment failure and high rates of recurrence 58 have been reported for both treatment agents.
9, 10 Patients experiencing one recurrence are 59 significantly more likely to experience further recurrences. 11 Current guidelines suggest that first 60 recurrences should be treated in the same way as initial CDI, but taking severity of disease into 61 consideration. 8 For second and subsequent recurrences, prolonged pulsed and/or tapered 62 vancomycin is sometimes used, 8 but with no clear preference for a particular regimen. 63
Fidaxomicin, a narrow-spectrum macrocyclic antimicrobial, has recently been approved for 64 treatment of CDI. In two phase III randomised, double-blind clinical trials, 200mg twice daily 65 fidaxomicin demonstrated non-inferiority to 125mg four times daily vancomycin for initial clinical 66 cure of CDI, but was superior to vancomycin in prevention of recurrence, and so for sustained clinical 67 cure. 12 It is possible that different dosing regimens of fidaxomicin may be beneficial in further 68 reducing CDI recurrence. We have previously described the efficacy of fidaxomicin for treatment of 69 simulated CDI in a validated human gut model. 13 Here we report the efficacy of four dosing 70 regimens to investigate the affects of extended, pulsed and tapered fidaxomicin on CDI resolution 71 using the same in vitro gut model. 72
Methods 74
Triple-stage chemostat gut model. 75
The gut model used in this experiment was based on that of MacFarlane et al 14 and comprises three 76 glass vessels arranged in a weir cascade formation. The model is inoculated with a pooled faecal 77 emulsion from healthy volunteers over 60 years of age (n=5), and top-fed with a complex growth 78 medium (dilution rate, 13.2 mL/h). 15 The vessels are maintained at 37°C and pH 5.5, 6.2 and 6.8 for 79 vessels 1, 2 and 3, respectively. All vessels are sparged with oxygen-free nitrogen to maintain an 80 anaerobic environment. The system has been validated against the intestinal contents of sudden 81 death victims, 14 and provides a close simulation of bacterial activities and composition in different 82 areas of the colon. 83
C. difficile strains 84
C. difficile strain 027 210 (BI/NAP1/PCR ribotype 027/ toxinotype III) was used in all experiments. 85
The strain was originally isolated during an outbreak of CDI at the Maine Medical Centre (Portland, 86 ME, USA) in 2005, and was kindly supplied by Dr Robert Owens (formerly, Maine Medical Centre).
Experimental design 88
Four gut models were run in total ( Figure 1 ). All models were inoculated with ~150 mL 10% (w/v) 89 faecal slurry prepared from pooled, C. difficile-negative faeces and left to equilibrate for 14-21 days 90 (Period A) to allow bacterial populations to achieve steady state. A single aliquot of C. difficile PCR 91 ribotype 027 spores (~10 7 cfu) was added into vessel 1 of each model, and left for a control period of 92 7 days (Period B), before a second aliquot of C. difficile spores was added, and clindamycin 93 instillation commenced to induce simulated CDI (33.9 mg/L , four times daily, 7 days, Period C). 94
Once germination, vegetative C. difficile proliferation (as measured by an increase in total viable 95 counts compared to spore counts), and high level toxin production was observed, simulated CDI was 96 deemed to be present. Fidaxomicin treatment regimens began the day after high level toxin was 97 All models were monitored for a further three weeks after treatment cessation with no further 113 interventions. Recurrence of simulated CDI was defined as a recurrence of vegetative C. difficile 114 proliferation (as measured by an increase in total viable counts compared to spore counts)and 115 associated toxin production. 116
Gut microbiota populations were enumerated on selective and non-selective agars every other day 117 during Period A, and daily thereafter, as recently described in detail. 16 C. difficile total viable counts 118 (vegetative cells plus spores), spore counts and toxin production were monitored daily as previously 119 described 16 from Period B onwards, and daily antimicrobial concentration was measured by large 120 plate bioassay from Period C onwards. 121
Monitoring for emergence of isolates of C. difficile with reduced susceptibility to fidaxomicin. difficile was detected (total counts and spore counts) at round the limit of detection, particularly in 172 models 2 (pulsed dosing), 3 (pulsed-tapered dosing), and 4 (tapered-pulsed), no signs of recurrent C. 173 difficile vegetative growth (sustained increase of total viable counts compared to spore counts) or 174 toxin production were observed in any of the four models. 175
Gut microbiota viable counts 176
Clindamycin instillation elicited large declines in bifidobacteria populations (at least 4 log 10 cfu/mL) in 177 all four models ( patients developing second or subsequent recurrences. 8 However, these regimens typically extend 213 the length and hence total amount of therapy given. The negative effects of vancomycin on the gut 214 microbiota (notably Bacteroides) [17] [18] [19] mean that extended vancomycin regimens are likely to disrupt 215 gut microbiota populations further and potentially also select for vancomycin-resistant enterococci. 216
Fidaxomicin has been linked to lower recurrence rates, 7,12 however recurrent disease can still occur 217 following standard fidaxomicin therapy (200mg/L, twice daily). We have therefore investigated 218 different regimens extending the 20 fidaxomicin doses over longer time frames, and compared this 219 to increasing the total number of doses to 40. 220
All four fidaxomicin dosing regimens investigated in this study successfully resolved simulated CDI in 221 a human gut model, with no signs of recurrent vegetative cell proliferation and toxin production. 222
We have previously noted reduced detection of C. difficile spores following fidaxomicin treatment 13 223 20 may cause it to adhere to spores, acting at 224 the earliest stages of germination and hence preventing recovery on CCEYL agar. A similar rapid 225 reduction in detected viable spores (2-3 log 10 cfu/mL) was observed following these dosing regimens, 226 although C. difficile spore recovery during treatment varied according to the dosing schedule. 227
Twenty days of fidaxomicin instillation (model 1, extended dosing) led to the greatest impact on C. 228 difficile recovery. In the other three models, the first 5 days of fidaxomicin appeared to be 229 insufficient to totally resolve simulated CDI. Toxin persisted at a titre of 1 in models 2 (pulsed dosing) 230 and 4 (tapered-pulsed dosing), and some evidence of continued C. difficile recovery was observed, 231 most notably in model 2 (pulsed dosing). In model 2, the second 5 days of fidaxomicin instillation 232 further reduced C. difficile total and spore counts and toxin detection. In models 3 (pulsed-tapered 233 dosing) and 4 (tapered-pulsed dosing), the tapered fidaxomicin administration following the initial 5 234 day pulsing supressed C. difficile recovery, although sporadic detection was observed following 235 cessation of instillation. Whilst suppression of C. difficile spore recovery has been postulated to be 236 linked to reduced rates of infection, 13 the clinical relevance of reduced spore recovery is not clear. 237
Therefore limited conclusions can be drawn regarding the differing levels of sporadic C. difficile 238 detection following the 4 different dosing regimens described here. However, all dosing regimens 239 were as successful as the previously described 7 days of fidaxomicin instillation in resolving 240 simulated CDI in the human gut model, with no signs of recurrent vegetative cell proliferation and 241 toxin production. 13 
242
The reasons for the delay in germination following clindamycin instillation in model 2 are unclear. In 243 model 2 (pulsed dosing), clindamycin remained detectable for ~10 days following the end of 244 instillation, whereas in in the other three models clindamycin was undetectable by between 3 and 7 245 days after clindamycin instillation. This may have supressed spore germination for longer, causing 246 delayed germination. Germination, when it occurred, was quantitatively similar in all four models. 247
Fidaxomicin has been reported to be relatively sparing of the gut microbiota. 21, 22 The effects of the 248 four extended fidaxomicin dosing regimens on gut microbiota populations were very similar, with 249 decreases in enterococci populations observed in all models. In contrast with previous reports, regimen cannot be determined. Tapered fidaxomicin dosing regimens in models 3 (pulsed-tapered 256 dosing) and 4 (tapered-pulsed dosing) initially reduced bifidobacteria populations to below the limit 257 of detection, but these subsequently recovered and remained stable for the rest of the experiments. 258
Variable effects of fidaxomicin exposure on bifidobacteria are likely due to different initial 259 populations of bifidobacteria species present in the donor stool samples.
13, 21, 22 Nevertheless, the 260 present studies provide evidence that tapering fidaxomicin exposure can suppress C. difficile and yet 261 allow recovery of gut microbiota populations. 262
As reported previously, 13 detectable fidaxomicin persisted in the gut model following the end of 263 instillation, and continued to be detected for the remainder of the experiments. Lower fidaxomicin 264 levels persisted after tapered dosing regimens, which may help to explain the recovery of 265 bifidobacteria in models 3 (pulsed-tapered dosing) and 4 (tapered-pulsed dosing). However, the 266 persisting fidaxomicin concentrations exceeded the MIC for the C. difficile strain used in these 267 models (0.25 mg/L). Persistence of fidaxomicin in stool samples has been shown during Phase I 268 human volunteer studies, 23 and microbiota diversity studies during Phase III studies have shown that 269 recovery of colonic microbiota begins during fidaxomicin therapy. 21 Tapered dosing regimens such as 270 those described here, may therefore allow low level persistence of fidaxomicin for longer periods of 271 time than standard dosing regimens, supressing recrudescence of C. difficile spores, but allowing 272 recovery of gut microbiota populations. While persistence of low level fidaxomicin for days or weeks 273 raises concerns of possible resistance selection, we found no evidence of emergence of reduced 274 susceptibility of C. difficile associated with the four prolonged dosing regimens studied here. 275 This study was initiated and financially supported by Astellas Pharma EMEA. 289
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